DK3043784T3 - Arylethere og anvendelser deraf - Google Patents

Arylethere og anvendelser deraf Download PDF

Info

Publication number
DK3043784T3
DK3043784T3 DK14842085.4T DK14842085T DK3043784T3 DK 3043784 T3 DK3043784 T3 DK 3043784T3 DK 14842085 T DK14842085 T DK 14842085T DK 3043784 T3 DK3043784 T3 DK 3043784T3
Authority
DK
Denmark
Prior art keywords
aryletes
Prior art date
Application number
DK14842085.4T
Other languages
Danish (da)
English (en)
Inventor
Jonas Grina
Stephen T Schlachter
Eli M Wallace
Hanbiao Yang
Darryl David Dixon
John A Josey
James P Rizzi
Bin Wang
Paul Wehn
Rui Xu
Original Assignee
Peloton Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peloton Therapeutics Inc filed Critical Peloton Therapeutics Inc
Application granted granted Critical
Publication of DK3043784T3 publication Critical patent/DK3043784T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B39/00—Halogenation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/13—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups
    • C07C205/20—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups having nitro groups and hydroxy groups bound to carbon atoms of six-membered aromatic rings
    • C07C205/21—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups having nitro groups and hydroxy groups bound to carbon atoms of six-membered aromatic rings having nitro groups and hydroxy groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C205/22—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups having nitro groups and hydroxy groups bound to carbon atoms of six-membered aromatic rings having nitro groups and hydroxy groups bound to carbon atoms of the same non-condensed six-membered aromatic ring having one nitro groups bound to the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/56—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and doubly-bound oxygen atoms bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C313/00—Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C313/02—Sulfinic acids; Derivatives thereof
    • C07C313/06—Sulfinamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/24—Sulfones; Sulfoxides having sulfone or sulfoxide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/36—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atoms of the amino groups bound to hydrogen atoms or to carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/38—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atom of at least one amino group being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfones
    • C07C317/40—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/38—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atom of at least one amino group being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfones
    • C07C317/42—Y being a hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/46—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/22—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C381/00—Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
    • C07C381/10—Compounds containing sulfur atoms doubly-bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/205—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring the aromatic ring being a non-condensed ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/225—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/257—Ethers having an ether-oxygen atom bound to carbon atoms both belonging to six-membered aromatic rings
    • C07C43/263—Ethers having an ether-oxygen atom bound to carbon atoms both belonging to six-membered aromatic rings the aromatic rings being non-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/257—Ethers having an ether-oxygen atom bound to carbon atoms both belonging to six-membered aromatic rings
    • C07C43/285—Ethers having an ether-oxygen atom bound to carbon atoms both belonging to six-membered aromatic rings having unsaturation outside the six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/93—Spiro compounds
    • C07C2603/94—Spiro compounds containing "free" spiro atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/257—Ethers having an ether-oxygen atom bound to carbon atoms both belonging to six-membered aromatic rings
    • C07C43/275—Ethers having an ether-oxygen atom bound to carbon atoms both belonging to six-membered aromatic rings having all ether-oxygen atoms bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/257—Ethers having an ether-oxygen atom bound to carbon atoms both belonging to six-membered aromatic rings
    • C07C43/29—Ethers having an ether-oxygen atom bound to carbon atoms both belonging to six-membered aromatic rings containing halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Luminescent Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
DK14842085.4T 2013-09-09 2014-09-05 Arylethere og anvendelser deraf DK3043784T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361875674P 2013-09-09 2013-09-09
US201461978421P 2014-04-11 2014-04-11
PCT/US2014/054375 WO2015035223A1 (en) 2013-09-09 2014-09-05 Aryl ethers and uses thereof

Publications (1)

Publication Number Publication Date
DK3043784T3 true DK3043784T3 (da) 2019-07-15

Family

ID=52628976

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14842085.4T DK3043784T3 (da) 2013-09-09 2014-09-05 Arylethere og anvendelser deraf

Country Status (33)

Country Link
US (7) US9908845B2 (enExample)
EP (4) EP3043784B9 (enExample)
JP (4) JP6486940B2 (enExample)
KR (1) KR102153772B1 (enExample)
CN (2) CN105530923B (enExample)
AU (1) AU2014318025B2 (enExample)
BR (1) BR112016005262B1 (enExample)
CA (1) CA2919397C (enExample)
CU (1) CU24385B1 (enExample)
CY (2) CY1122144T1 (enExample)
DK (1) DK3043784T3 (enExample)
EA (1) EA032124B1 (enExample)
ES (3) ES2784454T3 (enExample)
FI (1) FIC20253001I1 (enExample)
FR (1) FR25C1018I1 (enExample)
HR (2) HRP20201701T8 (enExample)
HU (3) HUE045462T2 (enExample)
IL (1) IL243888B (enExample)
LT (3) LT3417851T (enExample)
MX (1) MX2016002974A (enExample)
MY (1) MY199426A (enExample)
NL (1) NL301327I2 (enExample)
NO (1) NO2025022I1 (enExample)
PE (1) PE20160434A1 (enExample)
PL (2) PL3417851T3 (enExample)
PT (2) PT3417851T (enExample)
RS (2) RS58960B1 (enExample)
SG (1) SG11201601616SA (enExample)
SI (2) SI3043784T1 (enExample)
SM (1) SMT201900479T1 (enExample)
TW (2) TW201936572A (enExample)
UY (1) UY35731A (enExample)
WO (1) WO2015035223A1 (enExample)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6449845B2 (ja) 2013-03-15 2019-01-09 クロモセル コーポレイション 疼痛の処置のためのナトリウムチャネルモジュレーター
ES2784454T3 (es) 2013-09-09 2020-09-25 Peloton Therapeutics Inc Aril éteres y usos de los mismos
KR20160054570A (ko) 2013-09-10 2016-05-16 크로모셀 코포레이션 통증과 당뇨병의 치료를 위한 나트륨 통로 조절인자
ES2737148T3 (es) 2013-12-16 2020-01-10 Peloton Therapeutics Inc Análogos de sulfona y sulfoximina cíclicos y usos de los mismos
WO2016057242A1 (en) * 2014-10-10 2016-04-14 The Board Of Regents Of The University Of Texas System HIF-2α INHIBITORS FOR TREATING IRON OVERLOAD DISORDERS
US20180049995A1 (en) * 2015-03-11 2018-02-22 Peloton Therapeutics, Inc. Hif-2-alpha inhibitor polymorphs
EP3267792A4 (en) 2015-03-11 2018-09-26 Peloton Therapeutics, Inc. Compositions for use in treating pulmonary arterial hypertension
WO2016145045A1 (en) * 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Compositions for use in treating glioblastoma
EP3268362B1 (en) * 2015-03-11 2021-10-20 Peloton Therapeutics, Inc. Substituted pyridines and uses thereof
US10807948B2 (en) 2015-03-11 2020-10-20 Peloton Therapeutics, Inc. Aromatic compounds and uses thereof
US10335388B2 (en) 2015-04-17 2019-07-02 Peloton Therapeutics, Inc. Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof
US9796697B2 (en) 2015-06-12 2017-10-24 Peloton Therapeutics, Inc. Tricyclic inhibitors of HIF-2-alpha and uses thereof
CN105566406A (zh) * 2015-12-30 2016-05-11 江西胜富化工有限公司 一种氟代脱氧呋喃核糖的制备方法
WO2018031680A1 (en) * 2016-08-10 2018-02-15 Fronthera U.S. Pharmaceuticals Llc Novel compounds, uses and methods for their preparation
TW201825490A (zh) * 2017-01-11 2018-07-16 大陸商江蘇豪森藥業集團有限公司 吡咯並［２，３－ｃ］吡啶類衍生物、其製備方法及其在醫藥上的應用
WO2018160772A1 (en) 2017-02-28 2018-09-07 The United State Of America, As Represented By The Secretary, Department Of Health & Human Services Method of treating obesity, insulin resistance, non-alcoholic fatty liver disease including non-alcoholic steatohepatitis
TWI642658B (zh) 2017-11-01 2018-12-01 國立臺灣師範大學 茚並異喹啉衍生物的製備方法
WO2019100053A1 (en) 2017-11-20 2019-05-23 University Of Georgia Research Foundation, Inc. Compositions and methods for modulating hif-2α to improve muscle generation and repair
TW202003430A (zh) * 2018-03-28 2020-01-16 美商佩樂敦治療公司 以ＨＩＦ-２-α之抑制劑降低消化系統發炎之方法
JP7469297B2 (ja) 2018-05-18 2024-04-16 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング チオフェン誘導体
WO2020055883A1 (en) 2018-09-11 2020-03-19 Nikang Therapeutics, Inc. 2,3-DIHYDROBENZO[b]THIOPHENE DERIVATIVES AS HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORS
WO2020081695A1 (en) 2018-10-17 2020-04-23 Nikang Therapeutics, Inc. Indane derivatives as hypoxia inducible factor-2(alpha) inhibitors
CN112955130A (zh) * 2018-10-30 2021-06-11 佩洛通治疗公司 包含取代茚满的固体分散体和药物组合物及其制备和使用方法
CN109776607B (zh) * 2019-02-21 2021-06-04 青岛海洋生物医药研究院 芳基磷氧类和芳基磷硫类化合物及其制备方法和应用
UA128792C2 (uk) * 2019-04-18 2024-10-23 Ніканг Терапьютікс, Інк. ПОХІДНІ ТЕТРАГІДРО-1Н-ЦИКЛОПЕНТА[cd]ІНДЕНУ ЯК ІНГІБІТОРИ ФАКТОРА-2(АЛЬФА), ЩО ІНДУКУЄТЬСЯ ГІПОКСІЄЮ
EP4003974A1 (en) 2019-07-23 2022-06-01 Bayer Aktiengesellschaft Novel heteroaryl-triazole compounds as pesticides
EP4031542B1 (en) 2019-09-18 2025-10-15 Merck Sharp & Dohme LLC Small molecule inhibitors of kras g12c mutant
US11576889B2 (en) 2019-09-23 2023-02-14 The Board Of Regents Of The University Of Texas System Methods of identifying and treating patients with HIF-2 inhibitor resistance
GEP20247710B (en) 2019-10-28 2024-12-25 Merck Sharp & Dohme Llc Small molecule inhibitors of kras g12c mutant
EP4051266A1 (en) 2019-10-31 2022-09-07 Taiho Pharmaceutical Co., Ltd. 4-aminobut-2-enamide derivatives and salts thereof
CN112812136B (zh) * 2019-11-15 2022-04-12 武汉光谷亚太医药研究院有限公司 新型2,3-二氢化茚衍生化合物、制备方法和应用
TW202136248A (zh) 2019-11-25 2021-10-01 德商拜耳廠股份有限公司 作為殺蟲劑之新穎雜芳基-三唑化合物
IL293305A (en) 2019-11-26 2022-07-01 Merck Patent Gmbh The history of thiofan, their preparation and their use
WO2021106231A1 (en) 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
KR20220110524A (ko) * 2019-12-04 2022-08-08 아르커스 바이오사이언시즈 인코포레이티드 Hif-2알파의 억제제
CN111214484B (zh) * 2020-01-21 2021-04-06 北京工商大学 一种共轭聚合物和聚集诱导发光小分子共掺的纳米粒子及其制备方法和应用
CN113387848B (zh) * 2020-03-12 2022-11-22 上海交通大学 一种制备磺酰胺类化合物的合成工艺
CN115298165B (zh) * 2020-03-19 2024-09-17 艾库斯生物科学有限公司 作为HIF-2α抑制剂的四氢化萘和四氢喹啉化合物
US11420936B2 (en) 2020-04-16 2022-08-23 Nikang Therapeutics, Inc. Hypoxia inducible factor-2(alpha) inhibitors and their use in the treatment of diseases
WO2021215545A1 (en) 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c
EP4139299B1 (en) 2020-04-24 2025-12-17 Taiho Pharmaceutical Co., Ltd. Kras g12d protein inhibitors
TWI891782B (zh) 2020-05-06 2025-08-01 德商拜耳廠股份有限公司 作為殺蟲劑之新穎雜芳基三唑化合物
IL298966A (en) * 2020-06-11 2023-02-01 Betta Pharmaceuticals Co Ltd Bicyclic compound and application thereof
CN115667190B (zh) * 2020-06-17 2024-10-11 贝达药业股份有限公司 双环类化合物及其应用
EP4173639A4 (en) 2020-06-26 2024-03-13 RaQualia Pharma Inc. METHOD FOR SELECTING A CANCER PATIENT FOR WHICH COMBINATION THERAPY OF A RETINOID AND A CANCER TREATMENT AGENT WILL BE EFFECTIVE, AND COMBINATION DRUG OF A RETINOID AND A CANCER TREATMENT AGENT
US20230255972A1 (en) 2020-07-15 2023-08-17 Taiho Pharmaceutical Co., Ltd. Pyrimidine compound-containing combination to be used in tumor treatment
CN116134017B (zh) * 2020-09-24 2025-03-04 贝达药业股份有限公司 双环化合物及其应用
WO2022082337A1 (en) 2020-10-19 2022-04-28 Nikang Therapeutics, Inc. Process of preparing 3-fluoro-5 ( ( (1r, 2ar) -3, 3, 4, 4-tetrafluoro-1, 2a-dihydroxy-2, 2a, 3, 4-tetrahydro-1h-cyclopenta [cd] inden-7-yl) oxy) benzonitrile
WO2022082329A1 (en) * 2020-10-19 2022-04-28 Nikang Therapeutics, Inc. Processes of preparing 3-fluoro-5- ( ( (1s, 2ar) -1, 3, 3, 4, 4-pentafluoro-2a-hydroxy-2, 2a, 3, 4-tetrahydro-1h-cyclopenta [cd] inden-7-yl) oxy) -benzonitrile
WO2022086882A1 (en) 2020-10-21 2022-04-28 Nikang Therapeutics, Inc. Diagnostic and therapeutic methods for treatment of cancer with a hif-2(alpha) inhibitor
CN112724167B (zh) * 2021-01-13 2022-11-11 湖北恒安芙林药业股份有限公司 一种克立硼罗的制备方法
US11827614B2 (en) 2021-05-21 2023-11-28 Merck Sharp & Dohme Llc Synthetic pathway to belzutifan and crystalline phases of synthetic intermediates
JP2024521979A (ja) 2021-05-28 2024-06-04 大鵬薬品工業株式会社 Ｋｒａｓ変異タンパク質の小分子阻害剤関連出願の相互参照
CN113651735B (zh) * 2021-08-27 2022-04-15 中国药科大学 一种HIF-2α抑制剂PT2385的制备方法
US12145901B1 (en) 2021-09-17 2024-11-19 Arcus Biosciences, Inc. Process for preparing tetralin compounds
JP2024538131A (ja) * 2021-10-18 2024-10-18 ニカン セラピューティクス，インコーポレイテッド 膀胱癌処置のための低酸素誘導因子２（アルファ）阻害剤
WO2023160552A1 (zh) * 2022-02-22 2023-08-31 南京明德新药研发有限公司 一类螺环类化合物及其应用
CN116178223B (zh) * 2022-04-15 2024-12-03 上海皓鸿生物医药科技有限公司 一种Belzutifan及其中间体的制备方法
CN114656379B (zh) * 2022-04-27 2024-06-04 成都道合尔医药技术有限公司 一种立他司特中间体的合成方法
CN115611847B (zh) * 2022-10-13 2024-04-30 南方科技大学坪山生物医药研究院 一种Belzutifan的中间体的制备方法
AR131039A1 (es) * 2022-11-14 2025-02-12 Hoffmann La Roche ARIL TIOÉTERES COMO INHIBIDORES DE HIF-2a
WO2024209363A1 (en) 2023-04-06 2024-10-10 Pfizer Inc. Substituted indazole propionic acid derivative compounds and uses thereof as ampk activators
TW202515582A (zh) 2023-08-24 2025-04-16 日商大塚製藥股份有限公司 西區嘧啶(cedazuridine)之固定劑量組合
WO2025085748A1 (en) 2023-10-20 2025-04-24 Merck Sharp & Dohme Llc Small molecule inhibitors of kras proteins
CN118005840B (zh) * 2024-04-08 2024-06-14 西南石油大学 一种热增稠自破胶压裂液稠化剂及其制备方法和应用

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE705530C (de) 1932-01-23 1941-04-30 Chem Fab Von Heyden Akt Ges Verfahren zur Darstellung von Polychlorsubstitutionsprodukten des Diphenylaethers
FR1574139A (enExample) 1968-05-06 1969-07-11
US3905971A (en) * 1971-03-29 1975-09-16 Pfizer 2-Phenyl-as-triazine-3,5(2H,4H)diones
JPS4872169A (enExample) 1971-12-28 1973-09-29
GB1448696A (en) * 1973-05-29 1976-09-08 Pfizer 2-phqnyl-astriazine-3,4-2h,4h-diones
GB2017087B (en) 1978-03-03 1982-09-02 Roussel Lab Ltd Process for the preparation of xanthone derivatives
US4214103A (en) 1978-11-30 1980-07-22 Great Lakes Chemical Corporation Purification of brominated organic products
DE2938595A1 (de) * 1979-09-24 1981-04-23 Celamerck Gmbh & Co Kg, 6507 Ingelheim Verfahren zur herstellung von diphenylaethern
US4505929A (en) 1980-06-12 1985-03-19 The Dow Chemical Company Sulfur-substituted diphenyl ethers having antiviral activity
US4426385A (en) * 1980-10-16 1984-01-17 Union Carbide Corporation Insecticidal bicyclooxyphenyl ureas
DE3110894A1 (de) * 1981-03-20 1982-09-30 Celamerck Gmbh & Co Kg, 6507 Ingelheim Neue nitroaniline
DE3239449A1 (de) 1981-10-27 1983-05-05 CIBA-GEIGY AG, 4002 Basel Phenoxyphenyl- und pyridyloxyphenyl-derivate, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung
JPS58124758A (ja) 1982-01-20 1983-07-25 Fujisawa Pharmaceut Co Ltd ベンゼンスルホンアミド誘導体
DE3209878A1 (de) 1982-03-18 1983-09-29 Celamerck Gmbh & Co Kg, 6507 Ingelheim Verfahren zur herstellung von diphenylaethern
US4665097A (en) 1983-03-31 1987-05-12 Union Carbide Corporation Novel bicyclooxyaryl thioureas and process for preparation
US4664097A (en) 1984-05-09 1987-05-12 The Wistar Institute Of Anatomy & Biology Nuclear transplantation in the mammalian embryo by microsurgery and cell fusion
US4705955A (en) * 1985-04-02 1987-11-10 Curt Mileikowsky Radiation therapy for cancer patients
JPS635136A (ja) 1986-06-26 1988-01-11 Mitsubishi Electric Corp 内燃機関のアイドル回転数制御装置
JPS6351363A (ja) 1986-08-21 1988-03-04 Tekukemu:Kk アミノ基を有するジフエニ−ル化合物の製造方法
US5059609A (en) 1987-10-19 1991-10-22 Pfizer Inc. Substituted tetralins, chromans and related compounds in the treatment of asthma, arthritis and related diseases
IL105777A0 (en) * 1992-06-04 1993-09-22 Great Lakes Chemical Corp Method for the isolation of a partially brominated diphenyl ether product
EP0640618B1 (de) 1993-08-27 1999-10-20 F. Hoffmann-La Roche Ag Tetrahydronaphthalin-Peptidderivate
DE4431219A1 (de) * 1994-09-02 1996-03-07 Bayer Ag Selektive Herbizide auf Basis von Aryluracilen
US6887820B1 (en) 1995-12-06 2005-05-03 Japan Science And Technology Corporation Method for producing optically active compounds
US6184381B1 (en) 1995-12-06 2001-02-06 Japan Science & Technology Corp. Process for preparing optically active compounds
JP2001518103A (ja) 1997-03-20 2001-10-09 ビーエーエスエフ アクチェンゲゼルシャフト 置換２−ベンジル（ベンゾイル）ピリジン
US6596772B1 (en) 1999-08-27 2003-07-22 Sugen, Inc. Phosphate mimics and methods of treatment using phosphatase inhibitors
AU2002257794B8 (en) 2001-04-24 2007-02-15 D. Collen Research Foundation Use of hypoxia inducible factor 2alpha for curing neonatal respiratory distress syndrome and as a target for the treatment of pulmonary hypertension
JPWO2003064369A1 (ja) 2002-01-30 2005-05-26 キッセイ薬品工業株式会社 新規な甲状腺ホルモン受容体リガンド、それを含有する医薬組成物、およびそれらの用途
CA2463464A1 (en) 2003-04-28 2004-10-28 Auckland Uniservices Limited Methods of treatment and compositions therefor
SE0301906D0 (sv) * 2003-06-26 2003-06-26 Astrazeneca Ab New compounds
AU2004309287B2 (en) 2003-12-29 2008-07-31 Banyu Pharmaceutical Co., Ltd Novel 2-heteroaryl-substituted benzimidazole derivative
TW200611898A (en) 2004-05-28 2006-04-16 Speedel Experimenta Ag Organic compounds
MX2007002732A (es) 2004-09-10 2007-04-24 Pfizer Prod Inc Ligandos de difenil eter terapeuticos.
JP2008523145A (ja) 2004-12-13 2008-07-03 イーライ リリー アンド カンパニー リポキシゲナーゼ阻害剤としてのスピロ誘導体
WO2006083781A1 (en) 2005-01-31 2006-08-10 Merck & Co., Inc. Antidiabetic bicyclic compounds
TW200714597A (en) 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
JP2009515826A (ja) 2005-10-19 2009-04-16 エフ．ホフマン−ラ ロシュ アーゲー フェニル−アセトアミドｎｎｒｔ阻害剤
US8236826B2 (en) * 2005-12-05 2012-08-07 Otsuka Pharmaceutical Co., Ltd. Diarylether derivatives as antitumor agents
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
GB0526445D0 (en) * 2005-12-23 2006-02-08 Novartis Ag Organic compounds
ES2614090T3 (es) 2005-12-29 2017-05-29 Celtaxsys, Inc. Derivados de diamina como inhibidores de leucotrieno A4 hidrolasa
WO2007099423A1 (en) 2006-03-02 2007-09-07 Pfizer Products Inc. 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists
US20070244071A1 (en) * 2006-03-07 2007-10-18 Mount Sinai Hospital Treatment of proliferative diseases
ATE552245T1 (de) * 2006-05-15 2012-04-15 Merck Sharp & Dohme Antidiabetische bicyclische verbindungen
ZA200901163B (en) * 2006-08-23 2010-08-25 Neurogen Corp 2-Phenoxy pyrimidinone analogues
WO2008120761A1 (ja) 2007-03-30 2008-10-09 Nippon Shinyaku Co., Ltd. ヘテロアリール誘導体
CN101058535B (zh) 2007-05-25 2010-07-21 复旦大学 二(7-羟基-2,3-二氢-1-1h-茚基)醚类及其类似物、合成方法及应用
DE602008002205D1 (de) * 2007-06-06 2010-09-30 Torrent Pharmaceuticals Ltd Neuartige verbindungen
WO2008157273A1 (en) 2007-06-14 2008-12-24 Smithkline Beecham Corporation Chemical compounds
CN101407467A (zh) * 2007-10-12 2009-04-15 中国人民解放军军事医学科学院毒物药物研究所 N-取代芳烃苯胺/多取代二芳基醚类化合物,其制备方法及抗肿瘤应用
JP5383699B2 (ja) * 2007-12-05 2014-01-08 ビーエーエスエフ ソシエタス・ヨーロピア ピリジルメチル−スルホンアミド化合物
WO2009093133A1 (en) 2008-01-25 2009-07-30 Medichem, S.A. Method for determining the enantiomeric purity of indane derivatives
AU2009221375A1 (en) 2008-03-05 2009-09-11 F. Hoffmann-La Roche Ag 2-Aminoquinolines
US8188098B2 (en) 2008-05-19 2012-05-29 Hoffmann-La Roche Inc. GPR119 receptor agonists
AR074210A1 (es) * 2008-11-24 2010-12-29 Boehringer Ingelheim Int Derivados de pirimidina como inhibidores de ptk2-quinasa
US8691866B2 (en) 2008-12-10 2014-04-08 The General Hospital Corporation HIF inhibitors and use thereof
CA2747419C (en) * 2009-01-12 2014-07-08 Icagen, Inc. Sulfonamide derivatives
WO2010103438A1 (en) 2009-03-11 2010-09-16 Pfizer Inc. Substituted indazole amides and their use as glucokinase activators
WO2010137620A1 (ja) 2009-05-27 2010-12-02 武田薬品工業株式会社 フェノキシエチルアミン誘導体
CA2763040C (en) 2009-06-05 2018-05-01 Joan M. Caron Methods and compositions for the treatment of cancer
US8461164B2 (en) 2009-08-31 2013-06-11 Dow Agrosciences, Llc. Pteridines and their use as agrochemicals
JP2013509391A (ja) 2009-10-30 2013-03-14 グラクソ グループ リミテッド （３ｒ，６ｒ）−３−（２，３−ジヒドロ−１ｈ−インデン−２−イル）−１−［（１ｒ）−１−（２，６−ジメチル−３−ピリジニル）−２−（４−モルホリニル）−２−オキソエチル］−６−［（１ｓ）−１−メチルプロピル］−２，５−ピペラジンジオンの新規結晶性形態
US8853277B2 (en) * 2009-11-30 2014-10-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nitroxide therapy for the treatment of von Hippel—Lindau disease (VHL) and renal clear cell carcinoma (RCC)
WO2011105603A1 (ja) 2010-02-26 2011-09-01 株式会社日本触媒 フタロシアニン誘導体
GB201005589D0 (en) * 2010-04-01 2010-05-19 Respivert Ltd Novel compounds
US9024041B2 (en) 2010-04-08 2015-05-05 Respivert Ltd. P38 MAP kinase inhibitors
US9062072B2 (en) 2010-04-20 2015-06-23 Emory University Inhibitors of HIF and angiogenesis
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
WO2012014963A1 (ja) 2010-07-29 2012-02-02 アステラス製薬株式会社 縮環ピリジン化合物
EP2502917A1 (en) 2011-03-17 2012-09-26 Santhera Pharmaceuticals (Schweiz) AG Solid state crystalline forms of 4-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-1H-imidazole
US8865748B2 (en) 2011-06-06 2014-10-21 Akebia Therapeutics Inc. Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
UY34200A (es) 2011-07-21 2013-02-28 Bayer Ip Gmbh 3-(fluorovinil)pirazoles y su uso
EP2758377B1 (en) 2011-09-22 2017-08-02 Merck Sharp & Dohme Corp. Cycloalkylnitrile pyrazole carboxamides as janus kinase inhibitors
EP2768826A1 (de) 2011-10-17 2014-08-27 Bayer Intellectual Property GmbH Substituierte oxadiazolylpyridinone und - pyridazinone als hif - hemmer
EP2773641B1 (en) * 2011-10-31 2017-09-27 Xenon Pharmaceuticals Inc. Biaryl ether sulfonamides and their use as therapeutic agents
EP2807154B1 (en) 2012-01-28 2015-12-23 Merck Patent GmbH Azaheterocyclic compounds
US9556200B2 (en) 2012-03-06 2017-01-31 Takeda Pharmaceutical Company Limited Tricyclic compound
CA2877097C (en) 2012-06-21 2018-08-07 Eisai R&D Management Co., Ltd. Novel indanesulfamide derivative
WO2014031928A2 (en) 2012-08-24 2014-02-27 Philip Jones Heterocyclic modulators of hif activity for treatment of disease
EP2888253A4 (en) 2012-08-24 2016-01-06 Univ Texas HETEROCYCLIC HIF ACTIVITY MODULATORS FOR THE TREATMENT OF DISEASES
US20140128365A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors
CA2890897A1 (en) 2012-11-14 2014-05-22 The Board Of Regents Of The University Of Texas System Inhibition of hif-2.alpha. heterodimerization with hif 1.beta. (arnt)
JP5913752B2 (ja) * 2012-11-28 2016-04-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規インダニルオキシジヒドロベンゾフラニル酢酸
JP6283862B2 (ja) * 2012-12-07 2018-02-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規インダニルオキシジヒドロベンゾフラニル酢酸
ES2784454T3 (es) * 2013-09-09 2020-09-25 Peloton Therapeutics Inc Aril éteres y usos de los mismos
ES2737148T3 (es) 2013-12-16 2020-01-10 Peloton Therapeutics Inc Análogos de sulfona y sulfoximina cíclicos y usos de los mismos
EP3267792A4 (en) 2015-03-11 2018-09-26 Peloton Therapeutics, Inc. Compositions for use in treating pulmonary arterial hypertension
WO2016145045A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Compositions for use in treating glioblastoma
US10807948B2 (en) 2015-03-11 2020-10-20 Peloton Therapeutics, Inc. Aromatic compounds and uses thereof
EP3268362B1 (en) 2015-03-11 2021-10-20 Peloton Therapeutics, Inc. Substituted pyridines and uses thereof
US20180049995A1 (en) 2015-03-11 2018-02-22 Peloton Therapeutics, Inc. Hif-2-alpha inhibitor polymorphs
US10335388B2 (en) 2015-04-17 2019-07-02 Peloton Therapeutics, Inc. Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof
US9796697B2 (en) 2015-06-12 2017-10-24 Peloton Therapeutics, Inc. Tricyclic inhibitors of HIF-2-alpha and uses thereof

Also Published As

Publication number Publication date
CU24385B1 (es) 2019-03-04
PT3417851T (pt) 2020-10-12
US20170217891A1 (en) 2017-08-03
US20160251307A1 (en) 2016-09-01
EP3417851A1 (en) 2018-12-26
MY199426A (en) 2023-10-27
PT3043784T (pt) 2019-08-02
EA032124B1 (ru) 2019-04-30
MX2016002974A (es) 2016-06-02
HK1221667A1 (en) 2017-06-09
US10144711B2 (en) 2018-12-04
KR102153772B1 (ko) 2020-09-09
LT3417851T (lt) 2020-11-25
HUS2500021I1 (hu) 2025-05-28
PL3417851T3 (pl) 2020-12-14
CY1123433T1 (el) 2021-12-31
SI3417851T1 (sl) 2020-11-30
IL243888B (en) 2020-11-30
SG11201601616SA (en) 2016-04-28
TW201605775A (zh) 2016-02-16
US20200190031A1 (en) 2020-06-18
ES2823477T3 (es) 2021-05-07
CN110372550A (zh) 2019-10-25
LT3043784T (lt) 2019-08-12
HUE052080T2 (hu) 2021-04-28
CN110372550B (zh) 2021-08-24
US20180155279A1 (en) 2018-06-07
US9896418B2 (en) 2018-02-20
EP3417852B1 (en) 2020-02-19
CU20160030A7 (es) 2016-07-29
EP3417851B1 (en) 2020-07-22
EP3586835B1 (en) 2023-11-22
AU2014318025B2 (en) 2020-02-06
EP3043784A4 (en) 2017-04-05
NZ716281A (en) 2021-08-27
US20190119214A1 (en) 2019-04-25
CA2919397C (en) 2021-05-18
CY1122144T1 (el) 2020-11-25
EP3417852A1 (en) 2018-12-26
KR20160055199A (ko) 2016-05-17
US10597366B2 (en) 2020-03-24
AU2014318025A1 (en) 2016-02-18
US9908845B2 (en) 2018-03-06
ES2739433T3 (es) 2020-01-31
FR25C1018I1 (fr) 2025-07-18
PL3043784T3 (pl) 2019-10-31
EP3586835A1 (en) 2020-01-01
EP3043784B1 (en) 2019-05-15
JP2016534134A (ja) 2016-11-04
JP6486940B2 (ja) 2019-03-20
HRP20201701T1 (hr) 2021-04-02
EA201690549A1 (ru) 2016-11-30
US20170217892A1 (en) 2017-08-03
CA2919397A1 (en) 2015-03-12
HUE045462T2 (hu) 2019-12-30
IL243888A0 (en) 2016-04-21
CN105530923B (zh) 2019-07-23
ES2784454T3 (es) 2020-09-25
JP6918039B2 (ja) 2021-08-11
UY35731A (es) 2015-04-30
EP3043784B9 (en) 2019-11-20
NL301327I2 (nl) 2025-07-17
TWI657071B (zh) 2019-04-21
HRP20201701T8 (hr) 2022-01-07
JP2019089855A (ja) 2019-06-13
FIC20253001I1 (fi) 2025-05-05
JP2019070043A (ja) 2019-05-09
LTPA2025519I1 (enExample) 2025-06-10
RS60953B1 (sr) 2020-11-30
PE20160434A1 (es) 2016-05-25
JP2019089856A (ja) 2019-06-13
HRP20191298T1 (hr) 2019-10-18
SMT201900479T1 (it) 2019-09-09
CN105530923A (zh) 2016-04-27
BR112016005262B1 (pt) 2021-11-30
RS58960B1 (sr) 2019-08-30
US9969689B2 (en) 2018-05-15
TW201936572A (zh) 2019-09-16
BR112016005262A2 (pt) 2017-08-01
JP6746733B2 (ja) 2020-08-26
WO2015035223A1 (en) 2015-03-12
EP3043784A1 (en) 2016-07-20
SI3043784T1 (sl) 2019-08-30
USRE49948E1 (en) 2024-04-30
NO2025022I1 (no) 2025-05-12

Similar Documents

Publication Publication Date Title
DK3043784T3 (da) Arylethere og anvendelser deraf
DK3089994T3 (da) Fabs-in-tandem-immunglobulin og anvendelser deraf
DK3003039T3 (da) Methyl/fluor-pyridinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser og fluor-pyrimidinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser
DK2970460T3 (da) Anti-IL-33-antistoffer og anvendelser deraf
DK2968443T3 (da) Hepcidinanaloger og anvendelser deraf
DK2962100T3 (da) Tuberkulosebiomarkører og anvendelser deraf
DK3052485T3 (da) Heterocykliske forbindelser og anvendelser deraf
DK3381917T3 (da) Imidazopyridinforbindelser og anvendelser deraf
DK3027209T3 (da) Anti-Activin A-antistoffer og anvendelser deraf
DK3063144T3 (da) Antiparasitære og pesticid-isoxazolinforbindelser
IL245036B (en) Pesticidal compositions and related methods
DK2968173T3 (da) Heterocykliske forbindelser og anvendelser deraf
DK3030549T3 (da) Pyridazinonforbindelser og anvendelser deraf
DK3077467T3 (da) Sikkativsammensætning og anvendelse deraf
DK3058936T3 (da) Peptidsammensætning og anvendelser deraf
DK3003117T3 (da) Videolaryngoskop og laryngoskopindføringsdel
DK3052081T3 (da) Pastil
DK3029038T3 (da) Tetrazolinonforbindelse og anvendelse deraf
DK3060460T3 (da) Saddel
DK2964767T3 (da) Toksingener og fremgangsmåder til anvendelse deraf
DK3030519T3 (da) Tricykliske benzoxaborol-forbindelser og anvendelser deraf
DK3027598T3 (da) Oxoquinazolinyl-butanamidderivater
DK2956698T5 (da) Bindestrimler
DK2964374T3 (da) Synteseanordning og fremgangsmåde
DK2956476T3 (da) Ligandbindende molekyler og anvendelser deraf